PortfoliosLab logo
BCRX vs. JAZZ
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BCRX and JAZZ is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

BCRX vs. JAZZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

BCRX:

1.18

JAZZ:

0.02

Sortino Ratio

BCRX:

1.86

JAZZ:

0.24

Omega Ratio

BCRX:

1.22

JAZZ:

1.03

Calmar Ratio

BCRX:

0.77

JAZZ:

0.00

Martin Ratio

BCRX:

5.33

JAZZ:

0.00

Ulcer Index

BCRX:

11.83%

JAZZ:

10.42%

Daily Std Dev

BCRX:

55.74%

JAZZ:

34.50%

Max Drawdown

BCRX:

-97.74%

JAZZ:

-96.90%

Current Drawdown

BCRX:

-68.69%

JAZZ:

-43.13%

Fundamentals

Market Cap

BCRX:

$2.14B

JAZZ:

$6.72B

EPS

BCRX:

-$0.26

JAZZ:

$7.36

PEG Ratio

BCRX:

-0.28

JAZZ:

4.00

PS Ratio

BCRX:

4.26

JAZZ:

1.65

PB Ratio

BCRX:

56.59

JAZZ:

1.61

Total Revenue (TTM)

BCRX:

$503.49M

JAZZ:

$4.06B

Gross Profit (TTM)

BCRX:

$487.50M

JAZZ:

$3.45B

EBITDA (TTM)

BCRX:

$40.77M

JAZZ:

$1.28B

Returns By Period

In the year-to-date period, BCRX achieves a 37.90% return, which is significantly higher than JAZZ's -10.86% return. Over the past 10 years, BCRX has outperformed JAZZ with an annualized return of -0.96%, while JAZZ has yielded a comparatively lower -4.98% annualized return.


BCRX

YTD

37.90%

1M

40.14%

6M

46.88%

1Y

65.13%

3Y*

4.45%

5Y*

13.07%

10Y*

-0.96%

JAZZ

YTD

-10.86%

1M

6.81%

6M

-6.64%

1Y

0.72%

3Y*

-9.59%

5Y*

-0.82%

10Y*

-4.98%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BioCryst Pharmaceuticals, Inc.

Jazz Pharmaceuticals plc

Risk-Adjusted Performance

BCRX vs. JAZZ — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCRX
The Risk-Adjusted Performance Rank of BCRX is 8383
Overall Rank
The Sharpe Ratio Rank of BCRX is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of BCRX is 8484
Sortino Ratio Rank
The Omega Ratio Rank of BCRX is 8080
Omega Ratio Rank
The Calmar Ratio Rank of BCRX is 7979
Calmar Ratio Rank
The Martin Ratio Rank of BCRX is 8787
Martin Ratio Rank

JAZZ
The Risk-Adjusted Performance Rank of JAZZ is 4848
Overall Rank
The Sharpe Ratio Rank of JAZZ is 5252
Sharpe Ratio Rank
The Sortino Ratio Rank of JAZZ is 4343
Sortino Ratio Rank
The Omega Ratio Rank of JAZZ is 4242
Omega Ratio Rank
The Calmar Ratio Rank of JAZZ is 5151
Calmar Ratio Rank
The Martin Ratio Rank of JAZZ is 5050
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BCRX vs. JAZZ - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current BCRX Sharpe Ratio is 1.18, which is higher than the JAZZ Sharpe Ratio of 0.02. The chart below compares the historical Sharpe Ratios of BCRX and JAZZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

BCRX vs. JAZZ - Dividend Comparison

Neither BCRX nor JAZZ has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BCRX vs. JAZZ - Drawdown Comparison

The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum JAZZ drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for BCRX and JAZZ. For additional features, visit the drawdowns tool.


Loading data...

Volatility

BCRX vs. JAZZ - Volatility Comparison

BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 24.20% compared to Jazz Pharmaceuticals plc (JAZZ) at 15.96%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than JAZZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

BCRX vs. JAZZ - Financials Comparison

This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20212022202320242025
145.53M
897.84M
(BCRX) Total Revenue
(JAZZ) Total Revenue
Values in USD except per share items

BCRX vs. JAZZ - Profitability Comparison

The chart below illustrates the profitability comparison between BioCryst Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

65.0%70.0%75.0%80.0%85.0%90.0%95.0%100.0%20212022202320242025
96.9%
88.4%
(BCRX) Gross Margin
(JAZZ) Gross Margin
BCRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, BioCryst Pharmaceuticals, Inc. reported a gross profit of 140.97M and revenue of 145.53M. Therefore, the gross margin over that period was 96.9%.

JAZZ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Jazz Pharmaceuticals plc reported a gross profit of 793.22M and revenue of 897.84M. Therefore, the gross margin over that period was 88.4%.

BCRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, BioCryst Pharmaceuticals, Inc. reported an operating income of 21.23M and revenue of 145.53M, resulting in an operating margin of 14.6%.

JAZZ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Jazz Pharmaceuticals plc reported an operating income of -55.89M and revenue of 897.84M, resulting in an operating margin of -6.2%.

BCRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, BioCryst Pharmaceuticals, Inc. reported a net income of 32.00K and revenue of 145.53M, resulting in a net margin of 0.0%.

JAZZ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Jazz Pharmaceuticals plc reported a net income of -92.54M and revenue of 897.84M, resulting in a net margin of -10.3%.